A selective inhibitor of Na+/Ca2+ exchanger, SEA0400, preserves cardiac function and high-energy phosphates against ischemia/reperfusion injury.
The Ca2+ overload by Ca2+ influx via Na+/Ca2+ exchanger (NCX) is a critical mechanism in myocardial ischemia/reperfusion injury. We investigated protective effects of a novel selective inhibitor of NCX, SEA0400, on cardiac function and energy metabolism during ischemia and reperfusion. Langendorff-perfused rat hearts were exposed to 35 minutes global ischemia and 40 minutes reperfusion. Using 31P nuclear magnetic resonance spectroscopy, cardiac phosphocreatine (PCr), ATP, and pHi were monitored. SEA0400 did not change the basic cardiac function, but improved the recovery of left ventricular developed pressure (LVDP) after reperfusion (27.6 +/- 4.9 mm Hg in control, 101.2 +/- 19.3 mm Hg in 0.1 microM, and 115.5 +/- 13.3 mm Hg in 1 microM SEA0400, means +/- SE, n = 6, P < 0.05). SEA0400 reduced left ventricular end-diastolic pressure and increased coronary flow after reperfusion. SEA0400 improved the recoveries of cardiac phosphocreatine and ATP after reperfusion, but did not affect pHi. There were significant linear correlations between left ventricular developed pressure and cardiac phosphocreatine (r = 0.79, P < 0.05), and left ventricular developed pressure and ATP (r = 0.80, P < 0.05). However, SEA0400 increased the incidence and duration of reperfusion ventricular arrhythmias. SEA0400 added only after reperfusion also improved both the contractile function and energy metabolism. It is concluded that the selective inhibition of NCX may be effective to preserve high-energy phosphates and to improve cardiac function after reperfusion, but may not be able to prevent fatal arrhythmias.
Feng
Niu Chun
NC
Division of Cardiology, Internal Medicine III, Hamamatsu, Japan.
Satoh
Hiroshi
H
Urushida
Tsuyoshi
T
Katoh
Hideki
H
Terada
Hajime
H
Watanabe
Yasuhide
Y
Hayashi
Hideharu
H
D000200:Action Potentials / Q000187:drug effects; D000255:Adenosine Triphosphate / Q000032:analysis; D000814:Aniline Compounds / Q000494:pharmacology*; D000818:Animals; D002118:Calcium / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004734:Energy Metabolism; D006863:Hydrogen-Ion Concentration; D008297:Male; D009200:Myocardial Contraction / Q000187:drug effects; D015428:Myocardial Reperfusion Injury / Q000209:etiology* / Q000517:prevention & control; D009206:Myocardium / Q000378:metabolism*; D019906:Nuclear Magnetic Resonance, Biomolecular; D010477:Perfusion; D010647:Phenyl Ethers / Q000494:pharmacology*; D010710:Phosphates / Q000032:analysis*; D010725:Phosphocreatine / Q000031:analogs & derivatives / Q000032:analysis; D051381:Rats; D017207:Rats, Sprague-Dawley; D012964:Sodium / Q000378:metabolism; D019831:Sodium-Calcium Exchanger / Q000037:antagonists & inhibitors*; D016277:Ventricular Function, Left / Q000187:drug effects
D000814:Aniline Compounds; D010647:Phenyl Ethers; D010710:Phosphates; C430918:SEA 0400; D019831:Sodium-Calcium Exchanger; D010725:Phosphocreatine; C025403:phosphocreatinine; D000255:Adenosine Triphosphate; D012964:Sodium; D002118:Calcium